683 Capital Management LLC Sells 50,000 Shares of Immatics (NASDAQ:IMTX)

683 Capital Management LLC reduced its stake in Immatics (NASDAQ:IMTX - Free Report) by 7.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 650,000 shares of the company's stock after selling 50,000 shares during the quarter. 683 Capital Management LLC owned approximately 0.54% of Immatics worth $4,622,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of IMTX. abrdn plc boosted its holdings in Immatics by 49.2% during the fourth quarter. abrdn plc now owns 347,379 shares of the company's stock worth $2,470,000 after purchasing an additional 114,479 shares during the last quarter. Guggenheim Capital LLC purchased a new position in shares of Immatics in the 4th quarter worth approximately $101,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Immatics in the 4th quarter worth approximately $211,000. Schroder Investment Management Group grew its holdings in shares of Immatics by 52.6% in the fourth quarter. Schroder Investment Management Group now owns 427,994 shares of the company's stock valued at $2,953,000 after acquiring an additional 147,547 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Immatics during the fourth quarter valued at approximately $409,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Price Performance

Shares of NASDAQ IMTX traded down $0.20 during trading on Wednesday, reaching $4.39. 417,459 shares of the stock traded hands, compared to its average volume of 655,290. The stock has a market capitalization of $533.60 million, a P/E ratio of -6.64 and a beta of 0.87. Immatics has a 52-week low of $3.30 and a 52-week high of $13.77. The company has a 50-day moving average of $4.48 and a 200-day moving average of $6.12.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research note on Tuesday, April 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Immatics has a consensus rating of "Buy" and a consensus price target of $16.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.